Eli Lilly and Company (LLY) Halts UK Mounjaro Shipments Ahead of Planned Price Increase

We recently compiled a list of the 10 High Growth Pharma Stocks That Are Profitable in 2025. Eli Lilly and Company is one of them.

Eli Lilly and Company (NYSE:LLY) tops our list for being one of the high growth stocks. It is a global pharmaceutical leader and continues to drive growth in 2025 through innovative treatments in diabetes, obesity, cancer, and other chronic conditions. The company has seen strong momentum with its GLP-1-based therapies, particularly Mounjaro for diabetes and Zepbound for obesity, which are shaping its leadership in the metabolic treatment market.

In Q2 2025, Eli Lilly and Company (NYSE:LLY) reported robust sales of $15.56 billion, a 38% year-over-year increase, fueled by Mounjaro’s $5.2 billion (up 68%) and Zepbound’s $3.38 billion (up 172%). These results surpassed Wall Street expectations and enabled the company to raise its full-year 2025 revenue forecast to $60–$62 billion.

Beyond injectables, LLY is advancing oral obesity treatments. Late-stage trial data for orforglipron, an experimental oral therapy, showed over 12% average weight loss at the highest dosage and improvements in cardiovascular risk factors, supporting potential global regulatory submissions and market expansion.

Eli Lilly and Company (NYSE:LLY) is also managing regulatory and market dynamics, such as temporarily halting Mounjaro shipments in the UK ahead of a planned price increase. This aligns with broader pharmaceutical pricing trends influenced by U.S. policy and international market strategies.

While we acknowledge the potential of LLY as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you're looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the best short-term AI stock.

READ NEXT: 30 Stocks That Should Double in 3 Years and 11 Hidden AI Stocks to Buy Right Now.

Disclosure. None.